세계의 혈액형 검사 시장 : 시장 규모, 점유율 및 동향 분석(제품 및 서비스별, 검사법별, 기술별, 최종 용도별, 용도별, 지역별), 부문별 예측(2025-2030년)

Blood Typing Market Size, Share & Trends Analysis Report By Product & Services (Instruments, Reagents & Consumables), By Test (Antibody Screening), By Technique, By End Use, By Application, By Region, And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,266,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,655,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,434,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

세계의 혈액형 검사 시장 성장과 동향 :

Grand View Research, Inc.의 최신 보고서에 따르면 세계의 혈액형 검사 시장 규모는 2030년까지 34억 7,000만 달러에 이르며, 2025년부터 2030년까지 CAGR 8.61%로 확대될 것으로 추정됩니다.

이러한 성장은 교통사고나 긴급사태에 의해 필요한 수혈 건수 증가와 함께 법의학이나 산전 검사에 있어서의 혈액형 검사의 이용이 증가하고 있는 것이 배경에 있습니다.

혈액형 검사는 O, A, B, AB 그룹을 확인하고 기증자와 수령인 간의 적합성을 보장하고 Rh 요인을 결정하는 중요한 과정입니다. 이것은 발견되지 않으면 생명에 지장을 주는 신생아의 용혈성 질환(HDN)을 예방하기 위한 출생 전 검사에서 특히 중요합니다.

CDC에 의하면, 교통사고에 의해 연간 약 135만명의 생명이 빼앗기고 있어, 안전한 수혈을 확보하는데 있어서 혈액형 검사의 중요한 역할이 부각되고 있습니다. 그를 위한 혈액 샘플의 보관과 입수를 용이하게 하는 것으로, 시장의 성장을 더욱 뒷받침하고 있습니다. 수혈을 필요로 하는 사고나 외상 증가도 시장 성장의 주요인입니다.

게다가 잠재적인 합병증을 관리하기 위해 혈액형 검사를 필요로 하는 출생 전 검사도 중요한 촉진요인입니다.

게다가 시장 진출 기업은 진단 기술의 진보에 공헌하는 새로운 이니셔티브의 혁신과 도입에 노력하고 있습니다. 2022년 3월, Quotient Limited는 MosaiQ Extended Immunohematology Microarray의 CE 마크를 취득해, 단일 플랫폼상에서 항체 스크리닝, 항원 타이핑, ABO 그룹 분할에 의한 혈액형 검사 기능을 강화해, 워크플로우의 개선과 임상적 가치의 향상을 약속했습니다.

혈액형 검사 시장 : 분석 개요

• 시약 및 소모품은 제품 및 서비스 분야를 리드해, 2024년의 세계 매출의 71.4%를 차지했습니다. 신규 키트 개발을 위해 대기업이 광범위한 연구개발 이니셔티브를 취하고 있어, 예측 기간 중에도 유리한 성장이 전망됩니다.
• 검사 유형별로, 출생 전 검사 증가, 수혈 증가, 만성 질환 유병률 상승으로 항체 스크리닝이 2024년 시장 점유율 38%로 검사 부문을 선도한 반면 HLA 타이핑 부문은 시장에서 고도로 혁신적인 진단법의 개발로 예측 기간 동안 가장 빠른 CAGR로 성장할 것으로 예측되고 있습니다.
• 기술별로는 PCR 기반 마이크로어레이 기반이 2024년 시장 점유율 53.2%로 기술별 부문을 선도해 예측 기간 중 가장 빠른 CAGR로 성장할 것으로 예측됩니다.
• 용도별로는 진단 검사가 2024년 시장 점유율 54.2%로 용도별 부문을 지배했습니다.
• 최종 용도별로는 진단 검사 시설이 2024년에 43.4% 시장 점유율을 차지해 최종 용도 분야를 지배했습니다.
• 북미는 2024년에 42.83% 시장 점유율을 차지하여 시장을 독점했습니다.

목차

제1장 분석 방법 및 범위

제2장 주요 요약

제3장 혈액형 검사 시장 : 변동 요인, 경향, 범위

• 시장 연관 전망
  • 상위 시장 전망
  • 관련/부수 시장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 혈액형 검사 시장 : 분석 툴
  • 업계 분석 : Porter's Five Forces 분석
  • PESTEL 분석
• 가격 분석

제4장 혈액형 검사 시장 : 제품 및 서비스별 추정 및 동향 분석

• 혈액형 검사 시장 : 제품 및 서비스별 대시보드
• 세계의 혈액형 검사 시장의 변동 분석
• 세계의 혈액형 검사 시장 전망 : 제품 및 서비스별
• 기기
• 시약 및 소모품
• 서비스

제5장 혈액형 검사 시장 : 검사법별 추정 및 동향 분석

• 혈액형 검사 시장 : 검사법별 대시보드
• 세계의 혈액형 검사 시장의 변동 분석
• 세계의 혈액형 검사 시장 전망 : 검사법별
• 항체 스크리닝
• HLA 타이핑
• 교차 적합 시험
• ABO 혈액 검사
• 기타

제6장 혈액형 검사 시장 : 기술별 추정 및 동향 분석

• 혈액형 검사 시장 : 기술별 대시보드
• 세계의 혈액형 검사 시장의 변동 분석
• 세계의 혈액형 검사 시장 전망 : 기술별
• P0
• CR 기반 마이크로어레이 기반
• 분석 기반 기술
• 대규모 병렬 시퀀싱
• 기타

제7장 혈액형 검사 시장 : 용도별 추정 및 동향 분석

• 혈액형 검사 시장 : 용도별 대시보드
• 세계의 혈액형 검사 시장의 변동 분석
• 세계의 혈액형 검사 시장 전망 : 용도별
• 수혈
• 장기 이식
• 진단 검사

제8장 혈액형 검사 시장 : 최종 용도별 추정 및 동향 분석

• 혈액형 검사 시장 : 최종 용도별 대시보드
• 세계의 혈액형 검사 시장의 변동 분석
• 세계의 혈액형 검사 시장 전망 : 최종 용도별
• 병원 및 진료소
• 진단 검사 시설
• 혈액은행
• 기타

제9장 혈액형 검사 시장 : 지역별 추정 및 동향 분석(제품 및 서비스별, 검사법별, 기술별, 용도별, 최종 용도별)

• 지역별 대시보드
• 시장 규모 예측과 동향 분석(2018-2030년)
• 북미
  • 미국
  • 캐나다
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 노르웨이
  • 스웨덴
  • 덴마크
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 태국
• 라틴아메리카
  • 브라질
  • 멕시코
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 쿠웨이트

제10장 경쟁 구도

• 최근 동향과 영향 분석 : 주요 시장 진출기업별
• 기업/경쟁의 분류
• 벤더 상황
  • 주요 유통업체·채널 파트너 목록
  • 주요 고객
  • 주요 기업의 시장 점유율 분석(2024년)
  • Mesa Laboratories, Inc.(Agena Bioscience, Inc.)
  • Danaher Corporation(Beckman Coulter)
  • Bio-Rad Laboratories, Inc
  • DIAGAST
  • Grifols, SA
  • AXO Science
  • Merck KGaA
  • Thermo Fisher Scientific
  • Immucor, Inc.
  • BAG Diagnostics GmbH
  • Seegene Inc.

JHS

영문 목차

영문목차

Blood Typing Market Growth & Trends:

The global blood typing market size is estimated to reach USD 3.47 billion by 2030, expanding at a CAGR of 8.61% from 2025 to 2030, according to a new report by Grand View Research, Inc. This growth is fueled by the increasing usage of blood group typing in forensic sciences and prenatal testing, alongside the rising number of blood transfusions necessitated by road accidents and emergencies.

Blood group typing is a critical process that identifies the O, A, B, and AB groups, ensuring compatibility between donors and recipients and determining the Rh factor. This is particularly crucial in prenatal testing to prevent Hemolytic Disease of the Newborn (HDN), a condition that can be fatal if not detected. The market's growth is also supported by the growing number of road accidents and emergencies, which necessitate transfusions, and the increasing number of donations.

According to CDC, road accidents claim approximately 1.35 million lives annually, highlighting the critical role of blood group typing in ensuring safe transfusions. The advanced medical infrastructure in many countries, including increased storage capacities in hospitals, further supports the market's growth by facilitating the storage and availability of blood samples for typing and cross-matching. The rise in accidents and trauma cases requiring blood transfusions is another key factor for the market growth. The urgent need for transfusion in patients requiring surgical intervention also acts as a key driving factor.

Furthermore, prenatal testing, which requires blood group typing to manage potential complications, is another significant driver. The need for accurate blood group typing in pregnant women to prevent HDN is anticipated to further drive the market's growth. In addition, the increasing demand for blood group typing in forensic sciences contributes to the market's expansion.

Moreover, market players are striving to innovate and introduce new initiatives that contribute to the advancement of diagnostic technologies. These initiatives play a pivotal role in shaping the dynamics of the market, driving improvements in patient care, and addressing the evolving needs of healthcare providers. By leveraging their expertise and resources, market players introduce innovative solutions that enhance efficiency, accuracy, and accessibility within the healthcare ecosystem. For instance, in March 2022, Quotient Limited obtains CE Mark for MosaiQ Extended Immunohematology Microarray, enhancing blood typing capabilities with Antibody Screening, Antigen Typing, and ABO grouping on a single platform, promising improved workflow and clinical value. Such initiatives market players contribute to the broader healthcare market, with a focus on advancements in diagnostic technologies.

Blood Typing Market Report Highlights:

• Reagents and consumables led the product & services segment and accounted for 71.4% of the global revenue in 2024 and is anticipated to grow at lucrative growth over the forecast period, owing to extensive R&D initiatives being undertaken by major players for development of novel kits
• Based on test type, Antibody Screening led the test segment with a market share of 38% in 2024 due to the growing volume of prenatal testing, increasing transfusions and rising prevalence of chronic diseases, whereas HLA typing segment is estimated to grow at the fastest CAGR over the forecast period, owing to the development of advanced and innovative diagnostics in the market
• Based on technique, PCR-based and Microarray-based led the technique segment with a market share of 53.2% in 2024 and is anticipated to grow at the fastest CAGR over the forecast period
• Based on application, diagnostic testing dominated the application segment with a market share of 54.2% in 2024. The organ transplants segment is estimated to grow at the fastest CAGR over the forecast period
• Based on end-use, the Diagnostic laboratories dominate the end use segment with a market share of 43.4% in 2024, owing to large number of tests being done at the facilities
• North America dominated the market with the revenue share of 42.83% in 2024, owing to factors such as advanced healthcare infrastructure, rising prevalence of chronic diseases, and favorable regulatory environment

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product & Services
  • 1.2.2. Test
  • 1.2.3. Technique
  • 1.2.4. Application
  • 1.2.5. End-use
  • 1.2.6. Regional scope
  • 1.2.7. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product & services outlook
  • 2.2.2. Test outlook
  • 2.2.3. Technique outlook
  • 2.2.4. Application outlook
  • 2.2.5. End-use outlook
  • 2.2.6. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Blood Typing Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Rising demand for safe blood transfusions
    • 3.2.1.2. Growth in organ transplants
    • 3.2.1.3. Government support and public health initiatives
    • 3.2.1.4. Increased prenatal and neonatal screening
    • 3.2.1.5. Ai and digital innovation
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Poor blood service infrastructure
    • 3.2.2.2. Lack of awareness and skilled professionals
• 3.3. Blood Typing Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape
• 3.4. Pricing Analysis

Chapter 4. Blood Typing Market: Product & Services Estimates & Trend Analysis

• 4.1. Blood Typing Market: Product & Services Dashboard
• 4.2. Global Blood Typing Market Movement Analysis
• 4.3. Global Blood Typing Market by Product & Services Outlook
• 4.4. Instruments
  • 4.4.1. Instruments market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Reagents & Consumables
  • 4.5.1. Reagents & consumables market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.1.1. RBC reagents
      • 4.5.1.1.1. RBC reagents Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.5.1.2. Antisera reagents
      • 4.5.1.2.1. Antisera reagents Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.5.1.3. Anti Human Globulin Reagents
      • 4.5.1.3.1. Anti-Human Globulin reagents Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.5.1.4. Blood Saline Reagents
      • 4.5.1.4.1. Blood Saline reagents Market estimates and forecasts, 2018 to 2030 (USD Million)
• 4.6. Services
  • 4.6.1. Services market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Blood Typing Market: Test Estimates & Trend Analysis

• 5.1. Blood Typing Market: Test Dashboard
• 5.2. Global Blood Typing Market Movement Analysis
• 5.3. Global Blood Typing Market by Test Outlook
• 5.4. Antibody Screening
  • 5.4.1. Antibody Screening market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. HLA Typing
  • 5.5.1. Molecular diagnostics market estimates and forecasts 2018 to 2030 (USD Million)
• 5.6. Cross-Matching Tests
  • 5.6.1. Cross-Matching Tests market estimates and forecasts 2018 to 2030 (USD Million)
• 5.7. ABO blood Tests
  • 5.7.1. ABO blood Tests market estimates and forecasts 2018 to 2030 (USD Million)
• 5.8. Others
  • 5.8.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Blood Typing Market: Technique Estimates & Trend Analysis

• 6.1. Blood Typing Market: Technique Dashboard
• 6.2. Global Blood Typing Market Movement Analysis
• 6.3. Global Blood Typing Market by Technique Outlook
• 6.4. P0
  • 6.4.1. PO market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. CR based and Microarray based
  • 6.5.1. CR based and Microarray based market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Assay based techniques
  • 6.6.1. Assay based techniques market estimates and forecasts 2018 to 2030 (USD Million)
• 6.7. Massively Parallel Sequencing
  • 6.7.1. Massively Parallel Sequencing market estimates and forecasts 2018 to 2030 (USD Million)
• 6.8. Others
  • 6.8.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Blood Typing Market: Application Estimates & Trend Analysis

• 7.1. Blood Typing Market: Application Dashboard
• 7.2. Global Blood Typing Market Movement Analysis
• 7.3. Global Blood Typing Market by Application Outlook
• 7.4. Blood transfusions
  • 7.4.1. Blood transfusions market estimates and forecasts 2018 to 2030 (USD Million)
• 7.5. Organ transplants
  • 7.5.1. Organ transplants market estimates and forecasts 2018 to 2030 (USD Million)
• 7.6. Diagnostic testing
  • 7.6.1. Diagnostic testing market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Blood Typing Market: End-use Estimates & Trend Analysis

• 8.1. Blood Typing Market: End-use Dashboard
• 8.2. Global Blood Typing Market Movement Analysis
• 8.3. Global Blood Typing Market by End-use Outlook
• 8.4. Hospitals & clinics
  • 8.4.1. Hospitals & clinics market estimates and forecasts 2018 to 2030 (USD Million)
• 8.5. Diagnostic laboratories
  • 8.5.1. Diagnostic laboratories market estimates and forecasts 2018 to 2030 (USD Million)
• 8.6. Blood banks
  • 8.6.1. Blood banks market estimates and forecasts 2018 to 2030 (USD Million)
• 8.7. Others
  • 8.7.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Blood Typing Market: Regional Estimates & Trend Analysis by Product & Services, Test, Technique, Application and End-use

• 9.1. Regional Dashboard
• 9.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 9.3. North America
  • 9.3.1. U.S.
    • 9.3.1.1. Key country dynamics
    • 9.3.1.2. Regulatory framework/ reimbursement structure
    • 9.3.1.3. Competitive scenario
    • 9.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.3.2. Canada
    • 9.3.2.1. Key country dynamics
    • 9.3.2.2. Regulatory framework/ reimbursement structure
    • 9.3.2.3. Competitive scenario
    • 9.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
• 9.4. Europe
  • 9.4.1. UK
    • 9.4.1.1. Key country dynamics
    • 9.4.1.2. Regulatory framework/ reimbursement structure
    • 9.4.1.3. Competitive scenario
    • 9.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.4.2. Germany
    • 9.4.2.1. Key country dynamics
    • 9.4.2.2. Regulatory framework/ reimbursement structure
    • 9.4.2.3. Competitive scenario
    • 9.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.4.3. France
    • 9.4.3.1. Key country dynamics
    • 9.4.3.2. Regulatory framework/ reimbursement structure
    • 9.4.3.3. Competitive scenario
    • 9.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.4.4. Italy
    • 9.4.4.1. Key country dynamics
    • 9.4.4.2. Regulatory framework/ reimbursement structure
    • 9.4.4.3. Competitive scenario
    • 9.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.4.5. Spain
    • 9.4.5.1. Key country dynamics
    • 9.4.5.2. Regulatory framework/ reimbursement structure
    • 9.4.5.3. Competitive scenario
    • 9.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.4.6. Norway
    • 9.4.6.1. Key country dynamics
    • 9.4.6.2. Regulatory framework/ reimbursement structure
    • 9.4.6.3. Competitive scenario
    • 9.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.4.7. Sweden
    • 9.4.7.1. Key country dynamics
    • 9.4.7.2. Regulatory framework/ reimbursement structure
    • 9.4.7.3. Competitive scenario
    • 9.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.4.8. Denmark
    • 9.4.8.1. Key country dynamics
    • 9.4.8.2. Regulatory framework/ reimbursement structure
    • 9.4.8.3. Competitive scenario
    • 9.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 9.5. Asia Pacific
  • 9.5.1. Japan
    • 9.5.1.1. Key country dynamics
    • 9.5.1.2. Regulatory framework/ reimbursement structure
    • 9.5.1.3. Competitive scenario
    • 9.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.5.2. China
    • 9.5.2.1. Key country dynamics
    • 9.5.2.2. Regulatory framework/ reimbursement structure
    • 9.5.2.3. Competitive scenario
    • 9.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.5.3. India
    • 9.5.3.1. Key country dynamics
    • 9.5.3.2. Regulatory framework/ reimbursement structure
    • 9.5.3.3. Competitive scenario
    • 9.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.5.4. Australia
    • 9.5.4.1. Key country dynamics
    • 9.5.4.2. Regulatory framework/ reimbursement structure
    • 9.5.4.3. Competitive scenario
    • 9.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.5.5. South Korea
    • 9.5.5.1. Key country dynamics
    • 9.5.5.2. Regulatory framework/ reimbursement structure
    • 9.5.5.3. Competitive scenario
    • 9.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.5.6. Thailand
    • 9.5.6.1. Key country dynamics
    • 9.5.6.2. Regulatory framework/ reimbursement structure
    • 9.5.6.3. Competitive scenario
    • 9.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 9.6. Latin America
  • 9.6.1. Brazil
    • 9.6.1.1. Key country dynamics
    • 9.6.1.2. Regulatory framework/ reimbursement structure
    • 9.6.1.3. Competitive scenario
    • 9.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6.2. Mexico
    • 9.6.2.1. Key country dynamics
    • 9.6.2.2. Regulatory framework/ reimbursement structure
    • 9.6.2.3. Competitive scenario
    • 9.6.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6.3. Argentina
    • 9.6.3.1. Key country dynamics
    • 9.6.3.2. Regulatory framework/ reimbursement structure
    • 9.6.3.3. Competitive scenario
    • 9.6.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 9.7. MEA
  • 9.7.1. South Africa
    • 9.7.1.1. Key country dynamics
    • 9.7.1.2. Regulatory framework/ reimbursement structure
    • 9.7.1.3. Competitive scenario
    • 9.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.7.2. Saudi Arabia
    • 9.7.2.1. Key country dynamics
    • 9.7.2.2. Regulatory framework/ reimbursement structure
    • 9.7.2.3. Competitive scenario
    • 9.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.7.3. UAE
    • 9.7.3.1. Key country dynamics
    • 9.7.3.2. Regulatory framework/ reimbursement structure
    • 9.7.3.3. Competitive scenario
    • 9.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.7.4. Kuwait
    • 9.7.4.1. Key country dynamics
    • 9.7.4.2. Regulatory framework/ reimbursement structure
    • 9.7.4.3. Competitive scenario
    • 9.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 10. Competitive Landscape

• 10.1. Recent Developments & Impact Analysis, By Key Market Participants
• 10.2. Company/Competition Categorization
• 10.3. Vendor Landscape
  • 10.3.1. List of key distributors and channel partners
  • 10.3.2. Key customers
  • 10.3.3. Key company market share analysis, 2023
  • 10.3.4. Mesa Laboratories, Inc. (Agena Bioscience, Inc.)
    • 10.3.4.1. Company overview
    • 10.3.4.2. Financial performance
    • 10.3.4.3. Product benchmarking
    • 10.3.4.4. Strategic initiatives
  • 10.3.5. Danaher Corporation (Beckman Coulter)
    • 10.3.5.1. Company overview
    • 10.3.5.2. Financial performance
    • 10.3.5.3. Product benchmarking
    • 10.3.5.4. Strategic initiatives
  • 10.3.6. Bio-Rad Laboratories, Inc
    • 10.3.6.1. Company overview
    • 10.3.6.2. Financial performance
    • 10.3.6.3. Product benchmarking
    • 10.3.6.4. Strategic initiatives
  • 10.3.7. DIAGAST
    • 10.3.7.1. Company overview
    • 10.3.7.2. Financial performance
    • 10.3.7.3. Product benchmarking
    • 10.3.7.4. Strategic initiatives
  • 10.3.8. Grifols, S.A.
    • 10.3.8.1. Company overview
    • 10.3.8.2. Financial performance
    • 10.3.8.3. Product benchmarking
    • 10.3.8.4. Strategic initiatives
  • 10.3.9. AXO Science
    • 10.3.9.1. Company overview
    • 10.3.9.2. Financial performance
    • 10.3.9.3. Product benchmarking
    • 10.3.9.4. Strategic initiatives
  • 10.3.10. Merck KGaA
    • 10.3.10.1. Company overview
    • 10.3.10.2. Financial performance
    • 10.3.10.3. Product benchmarking
    • 10.3.10.4. Strategic initiatives
  • 10.3.11. Thermo Fisher Scientific
    • 10.3.11.1. Company overview
    • 10.3.11.2. Financial performance
    • 10.3.11.3. Product benchmarking
    • 10.3.11.4. Strategic initiatives
  • 10.3.12. Immucor, Inc.
    • 10.3.12.1. Company overview
    • 10.3.12.2. Financial performance
    • 10.3.12.3. Product benchmarking
    • 10.3.12.4. Strategic initiatives
  • 10.3.13. BAG Diagnostics GmbH
    • 10.3.13.1. Company overview
    • 10.3.13.2. Financial performance
    • 10.3.13.3. Product benchmarking
    • 10.3.13.4. Strategic initiatives
  • 10.3.14. Seegene Inc.
    • 10.3.14.1. Company overview
    • 10.3.14.2. Financial performance
    • 10.3.14.3. Product benchmarking
    • 10.3.14.4. Strategic initiatives

관련자료